Myelodysplastic Syndromes4m 0s
Selecting Right Patients for Early Initiation in HMAs in Low Risk MDS
Selecting the right patients for early initiation of hypomethylating agents (HMAs) in low-risk MDS involves identifying those with progressive cytopenias, poor prognostic mutations, or high-risk features despite low-risk classification.
hypomethylating agents (hmas)
disease progression
personalised treatment plans
low risk mds